
CME Group (CME) Stock Forecast & Price Target
CME Group (CME) Analyst Ratings
Bulls say
CME Group is well positioned by its dominant derivatives franchise, built through the 2007 CBOT merger, the 2008 Nymex acquisition, and the 2018 NEX deal, which broadened its reach into cash foreign exchange, fixed-income trading, and collateral optimization while preserving high incremental margins. The latest quarter reinforced that strength with record revenues of $1.74 billion, adjusted EPS of $3.02, market data and info services fees up 20% YoY, ADV up 16% YoY, and open interest at 128 million contracts, showing durable engagement across six asset classes. Its outlook is further supported by pricing power, a 27% stake in S&P Dow Jones Indices, accelerating product innovation including 368 new products year to date, and optionality from compute futures, 24/7 trading, and single stock futures, while management’s confidence in the CFTC litigation reduces a key regulatory overhang.
Bears say
CME Group is facing a softer fundamental backdrop as decelerating Average Daily Volume and weaker Revenue per Contract trends could pressure trading revenue and operating leverage. Its core franchise is also exposed to macro headwinds, including lower short-term interest rate expectations, a flatter forward yield curve, and widening credit spreads, which can reduce hedging demand across rates, credit, and energy. Competitive threats from FMX, CBOE, and ICE, along with possible market share erosion, poor integration execution after the 2018 NEX deal, and adverse regulatory changes, reinforce a cautious outlook.
This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.
CME Group (CME) Analyst Forecast & Price Prediction
Start investing in CME Group (CME)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About CME Group (CME) Forecast
CME Group (CME) Analyst Forecast & Price Prediction
Start investing in CME Group (CME)
Order type
Buy in
Order amount
Est. shares
0 shares